A Forward Chemical Screen in Zebrafish Identifies a Retinoic Acid Derivative with Receptor Specificity

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi://10.1371/journal.pone.0010004</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:10236034">http://nrs.harvard.edu/urn-3:HUL.InstRepos:10236034</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
A Forward Chemical Screen in Zebrafish Identifies a Retinoic Acid Derivative with Receptor Specificity

Bhaskar C. Das1,2*, Kellie McCarthn3, Ting-Chun Liu3, Randall T. Peterson4, Todd Evans3*

1 Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, New York, United States of America, 2 Department of Nuclear Medicine, Albert Einstein College of Medicine, New York, New York, United States of America, 3 Department of Surgery, Weill Cornell Medical College, Cornell University, New York, New York, United States of America, 4 Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America

Abstract

Background: Retinoids regulate key developmental pathways throughout life, and have potential uses for differentiation therapy. It should be possible to identify novel retinoids by coupling new chemical reactions with screens using the zebrafish embryonic model.

Principal Findings: We synthesized novel retinoid analogues and derivatives by amide coupling, obtaining 80–92% yields. A small library of these compounds was screened for bioactivity in living zebrafish embryos. We found that several structurally related compounds significantly affect development. Distinct phenotypes are generated depending on time of exposure, and we characterize one compound (BT10) that produces specific cardiovascular defects when added 1 day post fertilization. When compared to retinoic acid (ATRA), BT10 shows similar but not identical changes in the expression pattern of embryonic genes that are known targets of the retinoid pathway. Reporter assays determined that BT10 interacts with all three RAR receptor sub-types, but has no activity for RXR receptors, at all concentrations tested.

Conclusions: Our screen has identified a novel retinoid with specificity for retinoid receptors. This lead compound may be useful for manipulating components of retinoid signaling networks, and may be further derivatized for enhanced activity.

Introduction

Chemical genetics is an approach for identifying small molecules that alter the function of biological pathways, resulting in the induction or rescue of a specific phenotype [1,2,3,4]. Forward chemical genetics involves screening a library of compounds to find small molecules that generate a consistent phenotype in a biological assay, analogous to more traditional genetic screens. An advantage of chemical genetics over traditional genetics is the inherent conditional effect, and if it relates to human disease, a small molecule may serve as a starting point for drug discovery. The ability to modulate function specifically and rapidly makes small molecules especially useful tools for studying processes like development in which the timing of protein function is critical.

Chemical genetics involves screening a library of compounds to find small molecules that generate a consistent phenotype in a biological assay, analogous to more traditional genetic screens. An advantage of chemical genetics over traditional genetics is the inherent conditional effect, and if it relates to human disease, a small molecule may serve as a starting point for drug discovery.
vertebrate development [8]. The formation of the body axes and the development of a number of organ systems including retina, brain, heart, the urogenital system, and lungs are dependent on RA. The developmental defects resulting from vitamin A deficiency as well as the teratogenic effects of retinoid overdose are well documented [9]. Due to its effect on cell differentiation and proliferation, RA is now being used as a therapeutic tool in dermatology and oncology [10]. For example, RA provides a paradigm for differentiation therapy, an approach to treat malignant cells that are blocked for differentiation, so that they overcome the block and resume the process of differentiation into mature cells. However, apart from success in differentiation therapy for acute promyelocytic leukemia, retinoid therapies have not translated well to other cancers. While isotretinoin, a 13-cis-retinoic acid, has been widely used for a range of dermatological conditions, it also has severe teratogenic effects including craniofacial, cardiovascular, thymic and central nervous system malformations [11]. Therefore, the identification of retinoids with novel bioactivity is of clinical relevance [12]. The most important mechanism of RA activity is the regulation of gene expression. This is accomplished by its binding to nuclear retinoid receptors that are ligand-activated transcription factors [13]. Thus, RA acts as a transcriptional activator for a large number of other downstream regulatory molecules, including enzymes, transcription factors, cytokines, and cytokine receptors. Although the overwhelming majority of experimental studies have focused on RA receptor-dependent mechanisms, there have been indications of other, non-classical modes of action. This might occur through ligand interactions with enzymes such as protein kinase C, by direct activation of electrical synapses, or from interaction with putative cell surface receptors [14]. Toward a long-term goal of identifying new antagonists and agonists that target specific pathways, we focused on retinoid signaling, since it plays key roles in patterning the body axis, in the formation of many organs, and in maintaining tissue homeostasis.

Results

Derivation of a library of retinoid analogues

We first synthesized retinoic acid analogues of amides (retinoids) by coupling RA with amine derivatives (Fig. 1). First, retinoic acid was converted to retinoyl chloride, then in the presence of DMF, base, and aniline derivatives, we synthesized the corresponding 4-hydroxy phenyl amine derivatives (1, 2, 3, 4, 10, 11, 14, 15, 17, 18, 19, 20, 21 and 22). This procedure gave 80–90% yield. To develop efficacy and potency we synthesized novel retinoic acid analogue 8 [15] and then further derivatized to corresponding amide derivatives (5, 6, 7, 9, 12, 13 and 16) by amide coupling reactions.
According to this strategy we purified sufficient materials to generate a small library of these retinoid derivatives (Fig. 2) to screen for bioactivity in zebrafish embryos.

A developmental screen for analogue activity

After synthesis and purification of the compounds, they were screened for bioactivity using the zebrafish model. For this purpose, fertilized eggs were obtained from paired adults and cultured until 3–5 hours post-fertilization (hpf). Embryos were then grouped into individual wells of a 12 well plate, each well containing 3–10 embryos in 1 ml of 1X E3 buffer, 1% DMSO, and 1 mM Tris pH 7.5. Each test compound was diluted in DMSO to 10 mM stocks, and added to the cultured embryos at a final concentration of 10 μM. Treated embryos were cultured until 24 hpf and assessed for morphological alterations compared to embryos treated with vehicle (DMSO) alone.

In several independent experiments the effect of compounds was consistent and penetrant. Several of the compounds (10, 11, and 20) cause similar and very significant disruptions of the body axis (not shown). Dilutions of these three compounds were compared to evaluate their relative dose-response activities, and compound 10 was found to be most active, since it altered body axis formation when added at a concentration as low as 312 nM, a concentration at which the other two compounds are not active. We designated this lead compound BT10 and characterized its activity in more detail.

As shown in Fig. 3A, when BT10 is added to embryos at 5 hpf there is by 24 hpf a severe truncation of the body axis, although the embryo survives and forms a simple mass of pigmented tissue on the remaining yolk by 48 hpf (Fig. 3B). We do not believe that the effect is toxic, because the embryos are alive (even moving or "twitching", and continuing to develop pigmentation), although the "poster-

![Figure 2](https://www.plosone.org/figure/10.1371/journal.pone.0010004.g002)

**Figure 2. Compounds tested for activity altering normal zebrafish development.** Note that compounds 10, 11, and 20 were found to generate similar phenotypes, while compound 10 (red) was chosen for further study, since it had highest activity based on a dose response study. For simplicity, highly related compounds are grouped on the right.

doi:10.1371/journal.pone.0010004.g002
iorization” of the embryonic trunk is severe. If addition of the compound is delayed until 8 hpf, there is now a significant increase in development of the trunk, although head structures are largely undefined and the tail is much shorter than in control embryos at 24 hpf (Fig. 3C) or 48 hpf (Fig. 3D). These embryonic “posteriorization” phenotypes are consistent and similar to defects caused by addition of RA [16,17] and known RAR activators, such as DTAB [18].

Exposure to BT10 after 24 hpf disrupts cardiovascular development
A major advantage of using small molecules for manipulating pathways is that the activity can be tightly controlled, simply by the timing of delivery. We next sought to determine if BT10 remains active and is able to disrupt later stages of development. For this purpose, embryos were cultured with BT10 (or control vehicle) added at 24 hpf, and phenotypes were evaluated at 60 hpf. In multiple, independent experiments, BT10-treated embryos display a consistent and penetrant phenotype (n>50), comprising a characteristic malformation of the ventral yolk structure and disruption of normal heart tube development (Fig. 4). While the embryos show a minor posterior tail defect, the body trunk and gross head/brain structure are relatively normal. However, the heart tube that forms is thin, non-looping, and very weakly beating. This phenotype is also consistent with those reported for

Figure 3. BT10 added during early embryogenesis causes a major disruption of the body axis. Shown are representative embryos (from 3 experiments, for each sample n = 20) treated with BT10 at 10 µM (A-D) compared to embryos treated only with vehicle (DMSO) as control. BT10 was added at 5 hpf (A, B) or 8 hpf (C, D). DMSO alone was added at 5 hpf (E, F). Embryos were allowed to develop until 24 hpf (A, C, E) or 48 hpf (B, D, F). The position of the yolk is indicated in panels A and B. All embryos are viewed laterally, anterior to the right, dorsal at the top.
doi:10.1371/journal.pone.0010004.g003

Figure 4. BT10 causes specific cardiovascular defects when added at 24 hpf. Shown are representative embryos (from 3 experiments, for each sample n = 20) that were cultured between 24–60 hpf in the presence of DMSO alone (A, control) or BT10 (B). Note the defined morphological structure of the ventral yolk sac (arrow). A normal looping heart tube fails to develop in these embryos. Panels C and D show higher magnification views of representative control (C) and BT10-treated (D) embryos, respectively. The red block arrow indicates blood flowing through the normal control heart, which is not evident in the BT10-treated embryos. Views are lateral, anterior to the right, dorsal at the top.
doi:10.1371/journal.pone.0010004.g004
altered retinoid signaling, for example due to mutation in the *aldh1a2* gene [17].

Previous studies showed that excess RA eliminates or sharply reduces the amount of cardiac tissue in *Xenopus* [19] or zebrafish [20] embryos. More recent studies confirmed that heart tissue is severely diminished in zebrafish embryos treated with RA at a relatively high concentration (0.5 μM). At a relatively lower concentration (0.1 μM), ventricular tissue is preferentially sensitive to RA compared to atrial tissue [21]. Therefore, we next compared the effects of adding BT10 and RA during embryogenesis on cardiac development. For this purpose we compared the effect of RA at concentrations of BT10 that generates grossly similar body axis defects [low: 5 μM BT10, 0.1 μM ATRA; high: 15μM BT10, 0.3 μM ATRA]. We used quantitative RT-PCR (qPCR) to evaluate the effect of a pan-cardiomyocyte marker (*cmic2*) in addition to markers specific to ventricular cardiomyocytes (*vmhc*) and atrial cardiomyocytes (*ahmc*). As shown in Fig. 5A, when assayed at 24 hpf, both compounds severely diminish expression levels of cardiac markers when added at 5 μM. Notably, similar to ATRA, embryos treated with BT10 retain detectable (albeit substantially decreased) levels of the atrial marker, under conditions that eliminate detectable expression of the ventricular marker. When added at 24 hpf, the expression levels for these cardiac markers are much less disturbed (Fig. 5B), consistent with a morphogenetic defect rather than a failure to develop cardiomyocytes.

We therefore evaluated more closely the phenotype of disrupted heart tube development when similar concentrations of ATRA or BT10 are added later in embryogenesis. For this purpose we exposed embryos derived from transgenic fish carrying a *cmlc2:gfp* reporter, which facilitates visualization of heart tube formation and subsequent cardiac looping (Fig. 6). At these concentrations, heart tube formation occurs normally, and both atrial and ventricular chambers are readily apparent at 48 hpf. However, at 48 hpf the heart remains relatively linear compared to the control vehicle-treated embryos and fails to undergo proper looping morphogenesis. This looping defect likely contributes to the cardiac edema that develops by 60 hpf. Therefore both early and late effects of BT10 on cardiogenesis are consistent with RA-pathway-dependent defects in cell specification or heart tube looping, respectively.

**BT10 is an agonist for retinoid signaling**

In order to test directly if BT10 affects retinoid signaling, we analyzed the expression of specific known downstream targets of the pathway when the compound was added to cultured embryos, compared with ATRA or control (DMSO). For this purpose we again used concentrations of the compounds that gave grossly similar body axis defects (5 μM BT10, 0.1 μM ATRA). As shown in Fig. 7, BT10 and ATRA affect target gene expression levels with similar trends, measured by qPCR, consistent for specific activation of the retinoid pathway. For example, both BT10 and ATRA strongly activate expression of *cyp26a1* (a known downstream target that participates in negative feedback), while addition of either leads to significant decreases for genes that are repressed by excessive retinoids, *aldh1a2*, *pax2a*, and *egr2b* (*krox20*).

The specificity of action of BT10 was confirmed by evaluating the spatial expression pattern for retinoid target genes using *in situ* hybridization. As shown in Fig. 8, compared to control, *egr2b* expression in hindbrain segments rhombomere 3 and 5 is eliminated by BT10. Likewise, transcripts for *pax2a* in anterior structures including the midbrain-hindbrain boundary, optic stalk, and otic vesicle, in addition to the ventral pronephric ducts, is largely eliminated. Reduction in the expression domains of *pax2a* and *ntl* are much more subtle, but consistent with a loss of dorso-anterior mesoderm. The expression domain for *cyp26a1* is expanded throughout the embryo, compared to DMSO-treated embryos in which it is restricted to the posterior tailbud region. BT10 exposure causes a more extensive expansion of this marker compared to ATRA (although note that BT10 is used in this experiment at a much higher concentration compared to ATRA, which is overall more active). Therefore, as suggested by the qPCR data, BT10 appears to function by a mechanism similar but perhaps not identical to ATRA. Both compounds cause similar concentration-dependent changes in marker expression patterns.

**BT10 activity is specific to RAR and not RXR sub-types**

Finally, we performed experiments to test directly if BT10 functions by interaction with retinoid receptors, and we compared its specificity for receptor interaction with ATRA. Retinoids signal through two families of receptors, RAR and RXR, and there are three distinct genes that encode receptors for each family (α, β, and γ). We used a cell culture assay to express receptors and probe the specificity of ligand-receptor interaction [18]. In this assay, the three RARs are fused to the Gal4 DNA-binding domain, and co-transfected with a Gal4-dependent luciferase reporter, and the
three RXRs are tested for activation by expression in cells co-transfected with an RA-responsive luciferase reporter. As shown in Fig. 9, ATRA can interact with all 6 receptors, leading to strong activation of the luciferase reporters with a concentration-dependent response. In contrast, BT10 can activate each of the RAR receptors 10–40 fold, but the compound is inactive with respect to RXR activation, at the concentrations tested. Overall, the ability of BT10 to activate the RAR receptors is significantly reduced compared to ATRA, based on the dose response. Activities of the reporters are entirely dependent on co-expressed receptors. Since BT10 has a significantly lower activity for RARs compared to ATRA, we considered that BT10 might have low activity for RXRs, not detected under these conditions. However, even using a 10-fold higher concentration (100 μM) BT10 fails to activate the RXR receptors (Fig. 10). Above this concentration, BT10 is not tolerated by the cultured cells. Therefore, the compound is completely inert with respect to RXR activation, at all concentrations we were able to test. Therefore, BT10 shows interaction with a restricted class of retinoid receptors and appears to target RARs with specificity.

Discussion

We synthesized a small library of retinoic acid analogues and tested their activity by evaluating phenotypic changes caused in developing zebrafish embryos. Several of the compounds had
indicate normal expression pattern marking the 3rd and 5th rhomboanterior expression domains are largely abolished (panels). Note that in both ATRA and BT10 treated embryos, the normal expression pattern in the midbrain-hindbrain boundary (ntl panel), or more subtly inhibited (ntl, indicated by arrows in both panels). The reactions were monitored using TLC (Whatman PE SIL G/UV Fluorescence UV254). All the products prepared were purified by flash column chromatography on silica gel grade 62 (60–200 mesh, 150 Å). Proton nuclear magnetic resonance (1H-NMR) spectra were recorded in CDCl3 using a Bruker 300 MHz spectrometer (Waltham, MA) in positive ionization mode. Electrospray Ionization (ESI) mass spectra were obtained using ligands with defined and limited receptor specificity (reviewed in [12]). The active target of retinoids is a heterodimer composed of both RAR and RXR receptors. While RAR only interacts with RXR, the RXRs form functional complexes with a variety of additional nuclear receptors. Therefore, pan-agonists may have considerable off-pathway activation (or repression) that might be undesirable or teratogenic. For this purpose, the identification of compounds that are specific to receptor sub-types provide interesting leads of better-defined agonists for differentiation therapy. The gene expression analysis shows that BT10 does affect known targets of ATRA, although there is not a complete concordance with the sensitivity for target gene changes. Based on the morphology dose response study, ATRA is more active than BT10. While BT10 shows stronger effects in the qPCR assays shown here, the relative differences in gene induction or repression may reflect both the different concentrations of the compounds used in the assay, but also receptor complex specificity. This may reflect differential affinity of BT10, showing specificity for RAR and not RXR sub-types. Our results show the utility of combining focused small molecule derivation, applied to a biological screen using the zebrafish model, to identify new compounds with desired target activity and specificity.

Materials and Methods

Generation of compounds

All-trans retinoic acid (ATRA) was purchased from Sigma Chemical Co. (Sigma-Aldrich). The dry DMF was stored over 4-A sieves and degassed before use by bubbling nitrogen through it for at least 1 h. The other reagents and solvents were purchased from commercial sources (Aldrich or Fisher) and used without further purification. All reactions were conducted under a N2 atmosphere. The reactions were monitored using TLC (Whatman PE SIL G/UV Fluorescence UV254). All the products prepared were purified by flash column chromatography on silica gel grade 62 (60–200 mesh, 150 Å). Proton nuclear magnetic resonance (1H-NMR) spectra were recorded in CDCl3 using a Bruker 300 MHz instrument. Electrospray Ionization (ESI) mass spectra were determined on a Thermo Finnigan LCQ Classic ion trap mass spectrometer (Waltham, MA) in positive ionization mode.

Experimental detail of lead compound BT10: (2E,4E,6E,8E)-[3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoylamino]-[4-(alcohol)phenylamide]

A mixture of all-trans retinoic acid (ATRA) (100 mg, 0.33 mmol) in dry DMF (2 mL) and dry CH2Cl2 (2 mL) was stirred under nitrogen atmosphere for 1 hr. Oxalyl chloride

Figure 8. Changes in the expression patterns for known retinoid target genes confirm that BT10 is a retinoid agonist. Shown are representative embryos (n = 30) treated with vehicle (DMSO, left panels), 0.1 μM ATRA (middle panels), or 5 μM BT10 (right panels) and then analyzed by in situ hybridization at the 10 somite stage (cyp26a), 75% epiboly (ntl), the 18 somite stage (myod and pax2a), or the 26 somite stage (egr2b). Embryos are viewed laterally with anterior to the right (egr2b, cyp26a), dorsally with anterior to the right (myod, pax2a), or dorsally with animal pole to the top (ntl, arrows in both panels).
(1.25 mmol, 110 µL) was added drop by drop at 0°C. The deep red reaction mixture was stirred for another 1.5 h at room temperature under nitrogen atmosphere. After carefully removing the solvent, dry DMF was added (2 mL) immediately. At 0°C under nitrogen atmosphere, Retinoyl chloride solution was added dropwise to a solution of 4-aminobezyl alcohol (0.66 mmol, 81.28 mg) and triethylamine (1.00 mmol, 130 µL) in dry DMF (2 mL). The dark-colored reaction mixture was stirred at room temperature until TLC analysis indicated none remaining (about 2–3 h). The reaction was quenched with saturated NH₄Cl and extracted with ethyl acetate. The extracts were washed with H₂O and brine, then dried overage Na₂SO₄, and evaporated. The residue was purified by flash column chromatography using hexane/ethyl acetate (4/1) as the eluent to give BT10 as a yellow solid. 1H-NMR (300 MHz, CDCl₃): δ 7.58 (d, J = 6 Hz, 2H), 7.34 (d, J = 8 Hz, 2H), 7.28 (s, 1H), 7.12–6.90 (m, 1H), 6.32–6.19 (m, 4H), 5.82 (s, 1H), 4.67 (s, 2H), 2.06–2.03 (b, 4H), 1.74 (s, 3H), 1.67–1.62 (m, 4H), 1.51–1.49 (m, 2H) and 1.05 (s, 6H). 13C NMR (300 MHz, CDCl₃): δ 166.1, 152.2, 139.3, 138.4, 137.8, 136.7, 131.8, 130.4, 129.3, 128.7, 127.3, 122.8, 120.5, 65.7, 40.1, 34.4, 33.3, 29.0, 22.7, 19.8, 16.4 and 13.5. HRMS: (C₂₇H₃₅NO₂) Calcd ([M+H]+) 406.2746; found 406.2762.

Screening in zebrafish

For all experiments we used zebrafish that are a hybrid of AB and TU strains. All animal research was conducted according to national and international guidelines, with animals maintained and embryos obtained according to standard fish husbandry protocols.
The studies were approved prior to initiating the work by the Institutional Animal Care and Use Committee of Weill Cornell Medical College, and all animals were maintained by trained and approved Animal Institute staff of Weill Cornell Medical College. Embryos were obtained at the one cell stage from paired adults, and cultured in system water. For the initial screen we used embryos at 3 or 5 hpf. They were grouped into individual wells of a 12 well plate, each well containing 3–10 embryos in 1 ml of 1X E3 buffer (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), 1% DMSO, and 1 mM Tris pH 7.5. Compounds were diluted in DMSO to 10 mM stocks, and added to the cultured embryos to a final concentration of 10 μM. Subsequent experiments used further dilutions to determine dose response, and used later staged embryos to define the temporal response.

Gene expression analysis

Whole-mount in situ hybridization was performed essentially as described [23]. Hybridization was performed at 70°C, in 60% formamide buffer with digoxigenin-labeled RNA antisense probes. The probes used for in situ hybridization were prepared using either Sp6 or T7 polymerase with linearized templates. Probes were either as described [18], or were first isolated and subcloned by RT-PCR using whole embryo RNA.

For cyp26α1, Forward primer: TE2261, TCCGAACCTGCA-GAAGTCCTC, reverse primer: TE2262, GCTTCCACCA-GTTCTTGCTC, product size of 519 bp.

For eg2β, Forward primer: TE2265 GCCACTTCTCGAG-CACTGTC, reverse primer: TE2266TCTGCGAGATGTGA-GCTGTG, product size of 408 bp.

For quantitative real-time PCR assays, RNA was extracted from staged wildtype or morphant embryos using the RNeasy mini kit (Qiagen). First-strand cDNA synthesis was performed using the Superscript III First-Strand Synthesis System (Invitrogen). The cDNA was analyzed with Qiagen QuantiTect SYBR Green Mix (Qiagen) by quantitative RT–PCR using the Light Cycler 480II (Roche). All samples were prepared in triplicate, and each experiment was repeated at least 3 times using independent batches of embryos. The PCR cycle conditions were 95°C for 15 minutes, 94°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds) for 40 cycles. The Ct value data were analyzed using the 2−ΔΔCT method [24]. Primers used were:

- aldhlα2, F: ACTGCCAGGAGAGGTGAAGA, R: CAGGCTTGTACGTTGGAAG
- pax2α, F: GTGTCAAGCGCTTTCCAGAT, R: CCAGAGCCTCTGAACCACATC
- eg2β, F: AACACTGCCCAGCTCTGTG, R: GCTTCCACCA-GTTCTTGCTC
- cyp26α, F: TCCGTGGGTCTCATATCC
- egr2β, F: AACACTGCCCAGCCTCTGTG, R: GCTTCCACCA-GTTCTTGCTC
- pax2α, F: GTGTCAAGCGCTTTCCAGAT, R: CCAGAGCCTCTGAACCACATC

Receptor specificity assays

Hek293T cells were grown in DMEM containing 10% fetal bovine serum for 24 hr and 5 × 10⁴ cells were transfected with 200 ng pCMX-Gal-L-hRAR, 50 ng tk-px3-luc, and 1 ng renilla luciferase reporter plasmid or 200 ng pCMX-mRXR, 50 ng tk-apoA1-luc and 1 ng renilla plasmid, using Lipofetamine 2000, according to the manufacturer’s protocol (Invitrogen). Control transfections lacking receptors included only 30 ng tk-px3-luc or tk-apoA1-luc and 1 ng renilla luciferase reporter plasmid. Twenty-four hours following transfection, cells were treated with various concentrations (10⁻² M to 10⁻¹ M) of ATRA or BT10 diluted into DMSO, or were treated with DMSO alone. Cell lysates were collected 48 hr after transfection and were assayed for luciferase activity using the Dual-Luciferase® Reporter Assay System (Promega). The luciferase values were normalized to the renilla luciferase reporter, and results further normalized to the values obtained in cells treated with vehicle (DMSO) alone. The results were obtained from two independent experiments in assays done each time in duplicate.

Acknowledgments

We thank Ron Evans and Chetana Sachidanandan for generously providing plasmids.

Author Contributions

Conceived and designed the experiments: BCD TE. Performed the experiments: BCD KM TCL TE. Analyzed the data: BCD KM TCL RTP TE. Contributed reagents/materials/analysis tools: BCD RTP. Wrote the paper: BCD TE.

Figure 10. BT10 is selective for RAR receptors even at super-pharmacologic concentrations. Since BT10 has lower apparent affinity to all receptors compared to ATRA, the activity of BT10 was tested at 10 and 100 μM with each RAR isoform. Even at the highest concentration, there is no activation of RAR-dependent reporters, in contrast to activation of the control RARα receptor.

doi:10.1371/journal.pone.0010004.g010
References